Towards fast, routine blood sample quality evaluation by Probe Electrospray Ionization (PESI) metabolomics

Abstract

PESI-MS enables with its greatly simplified handling and fast result delivery the application field for high-throughput use in routine settings. In health care and research, pre-analytical errors often remain undetected and disrupt diagnosis, treatment, clinical studies and biomarker validations incurring high costs. This proof-of-principle study investigates the suitability of PESI-MS for robust, routine sample quality evaluation.

One of the most common pre-analytical quality issues in blood sampling are prolonged transportations times from bedside to laboratory promptly changing the metabolome. Here, human blood (n=50) was processed immediately or with a time delay of 3 h. The developed sample preparation method delivers ready-to-measure extracts in <8 min. PESI-MS spectra were measured in both ionization modes in 2 min from as little as 2 µl plasma allowing 3 replicate measurements. The mass spectra contained 1200 stable features covering a broad chemical space covering major metabolic classes (e.g. fatty acids, lysolipids, lipids). The time delay of 3 h was predictable by using 18 features with AUC > 0.95 with various machine learning and was robust against loss of single features.

Our results serve as first proof of principle for the unique advantages of PESI-MS in sample quality assessments. The results pave the way towards a fully automated, cost-efficient, user-friendly, robust and fast quality assessment of human blood samples from minimal sample amounts.

• Download figure
• Open in new tab

Competing Interest Statement

Employment: NB, PLG, SK, MT, AAB, WW, BP CBmed GmbH; EZ, CM, JS, YE Joanneum Research Forschungsgesellschaft mbH; SH, HN Shimadzu Corporation Honoraria/ Expert Testimony/Patents: None.

Clinical Trial

DRKS00024807

Funding Statement

Part of this work was carried out with the Competence Center CBmed, funded by the Austrian Federal Government within the COMET K1 Centre Program, Land Steiermark and Land Wien, and the Shimadzu Corporation, Kyoto, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ethical committee of the Medical University of Graz, Austria (31-116 ex 18/19, 16.01.2019)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes